Until BMSN officially puts out a PR that HemaX is approved for IND and P1 trials is gearing up, this will churn, assuming no other PR is released.
Today's PR is nice but then again, it isn't the key catalyst the stock needs to push up and away.
(0)
(0)
RIVULET MEDIA INC. (RIVU) Stock Research Links
-
-
-
-
-
-
-
